AP3

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Retrieved on: 
Tuesday, April 9, 2024
ACRV, Exchange, Health, Intelligence, Patient, Neoplasm, Paradigm, Research, AP3, Sale, Security (finance), Prospectus, Investment, Therapy, PIPE, Jefferies, Machine learning, Medicine

Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.

Key Points: 
  • Acrivon anticipates the gross proceeds from the oversubscribed PIPE to be approximately $130 million, before deducting fees to the placement agent and other offering expenses payable by the company.
  • The closing of the financing is expected to occur on April 11, 2024, subject to customary closing conditions.
  • “We are excited to announce this financing and thank our new and key existing investors who have shown their support for and confidence in Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • Jefferies acted as the exclusive placement agent in the private placement.

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
WEE1, Research, ACRV, Ovarian cancer, Carcinoma, Drug discovery, Patient, Neoplasm, Cell cycle, AP3, IC50, Proteomics, Abstract, AACR, PKMYT1, Clinical trial, Therapy, Toxicology, Mass spectrometry, GLP, Medicine, LDG, Pharmaceutical industry

“On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year for Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.

Key Points: 
  • “On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year for Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
  • We remain on track to present more mature clinical data during the first half of 2024.
  • Additionally, our novel WEE1/PKMYT1 inhibitor ACR-2316 continues to demonstrate robust and superior single-agent preclinical activity and tolerability as demonstrated in head-to-head benchmark studies.
  • As of December 31, 2023, the company had cash, cash equivalents and marketable securities of $127.5 million, which is expected to fund operations into the fourth quarter of 2025.

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Retrieved on: 
Tuesday, March 5, 2024
Drug resistance, Neoplasm, Drug design, AACR, Therapy, Patient, ACRV, Medicine, AP3, PKMYT1, WEE1, Gemcitabine, Pharmaceutical industry

WATERTOWN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company will be presenting data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5 – 10, 2024 in San Diego, CA.

Key Points: 
  • “The data we will be presenting reinforce the broad applicability of our highly differentiated, actionable AP3 platform technology,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • “ACR-2316 is our first fully internally-discovered development candidate which was rapidly generated through co-crystallography-based drug design and uniquely leverages AP3.
  • Our platform enables us to generate selective, potent single-agent active molecules, such as ACR-2316, that we believe can address some of the key limitations of current WEE1 and PKMYT1 inhibitors.
  • We look forward to presenting these two datasets at AACR next month.”

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

Retrieved on: 
Monday, March 4, 2024
Gene editing, Takeda Pharmaceutical Company, Neoplasm, Investment, Pfizer, Drug discovery, University, CFA, New Enterprise Associates, Proteomics, Doctor of Philosophy, NEA, Therapy, Patient, Radiopharmaceutical, ACRV, Medicine, AP3, Texas A&M University, Chemical engineering, Columbia University, Cowen Inc., Research, PFM, Biochemistry, Pharmaceutical industry

Dr. Palani added, “Acrivon is an entirely science-based company and its AP3 platform is a ground-breaking approach which is broadly applicable across drug discovery and development with significant unrealized potential -- not only in oncology but also in other areas including autoimmune and metabolic disorders, as dysregulated signaling ultimately underlies all diseases. The company currently is focused on oncology with a highly differentiated profile in this space. I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

Key Points: 
  • “Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • At PFM, Dr. Palani led public and private biotechnology investments, and served on the board of companies in the cell therapy and gene editing fields.
  • Prior to Cowen, Dr. Palani was in oncology drug development at Pfizer Inc. and Takeda Pharmaceuticals.
  • I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
Tuesday, February 27, 2024
Medicine, AP3, Patient, Event, Therapy, Conference, Webcast, Neoplasm, ACRV

WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a panel entitled “Gynecological Cancers Corporate Panel Discussion” on Tuesday, March 5, 2024 at 10:30 a.m.

Key Points: 
  • WATERTOWN, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a panel entitled “Gynecological Cancers Corporate Panel Discussion” on Tuesday, March 5, 2024 at 10:30 a.m.
  • ET at the TD Cowen 44th Annual Health Care Conference in Boston, MA.
  • To access the live webcast, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations .
  • A replay of the webcast will be available via the same link for 30 days following the event.

Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors

Retrieved on: 
Thursday, February 8, 2024
Wheaton College, Neoplasm, Research, Harvard University, Genetics, Patient, Head, IPO, Chemistry, Doctor of Philosophy, AP3, Senior counsel, Applied Genetic Technologies Corporation, Ipsen, Therapy, ACRV, Medicine, Proteomics, Suffolk University Law School, Biology, IP, Teva Pharmaceuticals, Management

“We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.

Key Points: 
  • “We are excited to welcome Ivana to our board of directors,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • Under her strong leadership, Vigil has evolved from inception through IPO, to an organization with two clinical-stage development programs.
  • Dr. Magovčević-Liebisch has served on the Board of Directors of Absci, Aeglea Therapeutics and Applied Genetic Technologies Corporation.
  • I look forward to working with Peter, the board, and the executive team to develop multiple promising drug candidates to improve patient lives.”

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Retrieved on: 
Tuesday, February 6, 2024
Neoplasm, AP3, Patient, Medicine, Webcast, Therapy, Event, ACRV, Conference

WATERTOWN, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, February 13, 2024 at 2:40 p.m.

Key Points: 
  • WATERTOWN, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Tuesday, February 13, 2024 at 2:40 p.m.
  • ET at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
  • To access the live webcast, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations.
  • A replay of the webcast will be available via the same link for 30 days following the event.

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, January 12, 2024
AP3, Neoplasm, ACRV, Patient, Therapy, Employment, Medicine, Proteomics

WATERTOWN, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, announced that the company approved a grant of an equity award under its 2023 Inducement Plan to one employee.

Key Points: 
  • WATERTOWN, Mass., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, announced that the company approved a grant of an equity award under its 2023 Inducement Plan to one employee.
  • The equity award was granted in the form of stock options and has a grant date of January 11, 2024.
  • The employee received options to purchase 99,300 shares of Acrivon common stock.
  • The inducement grant was approved by Acrivon’s Board of Directors, as required by Nasdaq Rule 5635(c)(4), and was granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4).

Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Webcast, AP3, Event, ACRV, Conference, Patient, Medicine, Neoplasm, Therapy

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will present a company overview on Thursday, January 11, 2024 at 11:15 a.m. PT at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Key Points: 
  • WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will present a company overview on Thursday, January 11, 2024 at 11:15 a.m. PT at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
  • To access the live webcast, visit the Events & Presentations page within the investor section of the company’s website at https://ir.acrivon.com/news-events/events-presentations .
  • A replay of the webcast will be available via the same link for 30 days following the event.

Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, January 3, 2024
IO, Biology, Research, Bristol Myers Squibb, Disease, Merck Serono, Therapy, Merkel-cell carcinoma, Cancer, Molecular biology, Master of Science, Novartis, M.A, Biochemistry, Proteomics, Neoplasm, Serono, Merck, Ipilimumab, AP3, Patient, ACRV, Medicine, Phase II, Pharmacology, Pharmaceutical industry

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.

Key Points: 
  • WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics or AP3, today announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer.
  • “Jean-Marie has over twenty years of successful experience in oncology drug development, and we are delighted to have him join Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • “During his impressive career, he has effectively executed on advancing drugs from early development through regulatory approval, at both pharma and biotech companies.
  • Prior to Dragonfly, Dr. Cuillerot was the chief medical officer of Agenus, where he led development activities for five investigational therapies.